Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of abiraterone in relapsed epithelial ovarian cancer
2013-000293-29Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Objective response rate and Clinical activity by imaging and/or CA125. Status: unknown.
02
Drugs
abiraterone
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2013-000293-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000293-29.